Medicina· 2026Q2
Predictive Value of On-Treatment Alpha-Fetoprotein Change for Lenvatinib Response in Patients with Hepatocellular Carcinoma: A Real-World Retrospective Study in Vietnam
- 0citations
- Q2SCImago
- 2026year
Short summary
A 40% decrease in alpha-fetoprotein (AFP) after the first lenvatinib dose predicts significantly higher objective response rates (ORR) and disease control rates (DCR) in hepatocellular carcinoma (HCC) patients.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine